However, clinical responses to BRAF and MEK inhibitors are often not durable due to acquisition of resistance after treatment [15–17], highlighting the need to identify novel melanoma vulnerabilities that could be exploited for new treatments. The gene discussed is MAP2K7; the disease is melanoma.